Tvardi Proves STAT3 Can Be Hit With Prodrug; Phase 1 Data Supports Twice-Daily Dosing

Tvardi Therapeutics released Phase 1 data for TTI-109, its next-generation STAT3 inhibitor, on Tuesday. The healthy volunteer study showed the prodrug achieved target engagement with a tolerability profile that supports twice-daily oral dosing. The stock, which trades over the counter, barely moved on the session – a reflection of low liquidity, not the data's signal.

TTI-109 is a prodrug of TTI-101, the company's first-generation STAT3 inhibitor. The prodrug design improves oral bioavailability and nearly eliminates the food effect that complicated TTI-101's pharmacokinetics. Plasma concentrations were dose-proportional and stayed above the predicted therapeutic threshold for 24 hours at doses above 400 mg, the company said.

Target engagement was measured as reductions in phosphorylated STAT3 in peripheral blood mononuclear cells. A 50% drop occurred at the 400 mg dose, with deeper suppression at higher levels. No serious adverse events were reported. The most common side effects were mild gastrointestinal events, all self-limiting. CEO Imran Alibhai told analysts the lower peak-to-trough ratio could reduce side effects in chronic dosing, which matters for indications like idiopathic pulmonary fibrosis where patients take the drug for months.

STAT3 has been a notoriously difficult target. Earlier efforts by other biotechs ran into toxicity or poor oral exposure, earning the pathway a reputation as undruggable. Tvardi's prodrug strategy appears to side-step both problems, analysts on the call said. The readthrough for the sector is that STAT3, with the right chemical approach, may be addressable in both oncology and fibrosis.

The company plans to move TTI-109 into a multiple-ascending dose study in cancer patients later this year. TTI-101, the first-generation drug, is already in Phase 2 for idiopathic pulmonary fibrosis and hepatocellular carcinoma. If TTI-109's profile holds in patients, it could eventually replace TTI-101 in those indications – a swap that would simplify dosing and improve tolerability over the long run.

Nine analysts from Piper Sandler, Cantor Fitzgerald, BTIG, JonesTrading, Raymond James, Barclays, Oppenheimer, H.C. Wainwright, and Lucid Capital Markets joined the call. Several probed the fibrosis angle, given the long development timelines typical for that indication. Alibhai pointed to the prodrug's pharmacokinetic advantages as the basis for a cleaner chronic safety profile.

Tvardi has not disclosed a timeline for releasing the MAD data or for selecting a lead indication. The company's shares are listed on the OTC market and trade with limited volume, meaning price discovery after catalysts like this one is slow.